While nanomedicine or small molecular drugs are the kind of medications that major biopharmaceutical companies are developing, there are still a handful others who harness the benefits of high molecular weight and non-absorbed polymeric drugs. These types of medications are highly advantageous as these exude long-term safety profiles. Compared to small molecular medications, these drugs can easily be flushed out of the body and thus are less toxic.
Relypsa, Inc. is one of the biopharmaceutical companies that leverage the development of their products on these non-absorbed, high molecular weight polymeric drugs. The company focuses in the designing and the advancement of their drug products that are intended as treatment for cardiovascular, renal and metabolic diseases. The company has just filed for a new drug application to the Food and Drug Administration (FDA) of the United States for the their lead product, the Patiromer for Oral Suspension.
Patiromer for Oral Suspension is another version of the company’s Patiromer FOS that is already being commercialized globally. This product is intended for the treatment of hyperkalemia, a serious condition wherein patients would experience elevated levels of potassium in their blood. The new version of the Patiromer is set to be developed by the company under eight clinical trials. The business has intellectual property over the drug that is set to expire sometime in 2030. There are not that many medications available for hyperkalemia, and Relypsa has once again taken on the challenge of providing patients with alternative options on how to treat their disease.
The business advances the development of this product through their proprietary polymer drug discovery technology platform. It is in Redwood City, California that the business holds its corporate office. Relypsa remains publicly traded on the NASDAQ where it markets its common shares using the ticker symbol RLYP.